文献速递肿瘤 PET/CT核素与放射性配体治疗

用于机器人辅助68Ga-PSMA放射引导手术的DROP-INβ探测器:前列腺癌标本的首次离体技术评估

A DROP-IN beta probe for robot-assisted 68Ga-PSMA radioguided surgery: first ex vivo technology evaluation using prostate cancer specimens.
PubMed 文献 · EJNMMI Res · 2020-08-06

本研究工程化并验证了一种新型DROP-INβ探测器,用于机器人辅助的β放射引导手术。7例PSMA-PET阳性前列腺癌患者接受术中约70 MBq 68Ga-PSMA-11注射后行机器人辅助前列腺切除术及扩大盆腔淋巴结清扫,离体标本测试显示当肿瘤距标本表面<1 mm时信号本底比>5,2例患者的PSMA-PET阳性淋巴结也被检出(S/B>3)。结论认为该技术在此机器人背景下可行。

要点

  • DROP-INβ探测器在离体标本中可识别68Ga-PSMA-11热区,肿瘤距表面<1 mm时S/B>5。
  • 2例患者的PSMA-PET阳性淋巴结经探测器确认,S/B>3。
  • DROP-IN设计旋转自由度和prograsp工具操作使术者能自主进行β示踪。

核心结论

  • 本研究通过离体实验证明,使用DROP-INβ探测器在机器人辅助背景下进行β放射引导手术是可行的。
  • 未来若转化至体内环境,该技术可能有助于检测前列腺表面的肿瘤残留及确认PSMA-PET阳性淋巴结。

研究设计与样本

  • 研究纳入7例PSMA-PET阳性肿瘤的前列腺癌患者,术中额外注射约70 MBq 68Ga-PSMA-11,随后行机器人辅助前列腺切除术及扩大盆腔淋巴结清扫。
  • 利用上述手术标本离体验证DROP-INβ探测器原型性能,该原型将闪烁探测器与适配12 mm trocar及prograsp器械的外壳整合。
  • 探测器及外壳经蒙特卡罗模拟优化后,在机器人设置下进行测试。

主要发现

  • 离体设置中,机器人定位的探测器能够识别手术标本中含68Ga-PSMA-11的热点。
  • 当病理确认肿瘤位于标本表面下<1 mm时,信号本底比(S/B)>5。
  • 2例患者中发现含68Ga-PSMA-11且PET阳性的淋巴结,DROP-INβ探测器确认S/B>3。
  • DROP-IN设计的旋转自由度和prograsp工具操作能力使术者能够自主进行β示踪。

关键数值与推荐

  • 肿瘤距标本表面<1 mm时,DROP-INβ探测器识别68Ga-PSMA-11热点的S/B>5。
  • PSMA-PET阳性淋巴结经DROP-INβ探测器确认的S/B>3。

临床怎么用

  • 该离体研究支持在机器人辅助手术中利用DROP-INβ探测器进行β放射引导,以探测前列腺表面肿瘤残留和确认PSMA-PET阳性淋巴结,但尚需未来体内转化验证。

局限性

  • 本研究为离体技术评估,尚未在体内环境中验证。
  • 样本量较小(7例患者),且为首次原型测试。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recently, a flexible DROP-IN gamma-probe was introduced for robot-assisted radioguided surgery, using traditional low-energy SPECT-isotopes. In parallel, a novel approach to achieve sensitive radioguidance using beta-emitting PET isotopes has been proposed. Integration of these two concepts would allow to exploit the use of PET tracers during robot-assisted tumor-receptor-targeted. In this study, we have engineered and validated the performance of a novel DROP-IN beta particle (DROP-INβ) detector. METHODS: Seven prostate cancer patients with PSMA-PET positive tumors received an additional intraoperative injection of ~ 70 MBq 68Ga-PSMA-11, followed by robot-assisted prostatectomy and extended pelvic lymph node dissection. The surgical specimens from these procedures were used to validate the performance of our DROP-INβ probe prototype, which merged a scintillating detector with a housing optimized for a 12-mm trocar and prograsp instruments. RESULTS: After optimization of the detector and probe housing via Monte Carlo simulations, the resulting DROP-INβ probe prototype was tested in a robotic setting. In the ex vivo setting, the probe-positioned by the robot-was able to identify 68Ga-PSMA-11 containing hot-spots in the surgical specimens: signal-to-background (S/B) was > 5 when pathology confirmed that the tumor was located < 1 mm below the specimen surface. 68Ga-PSMA-11 containing (and PET positive) lymph nodes, as found in two patients, were also confirmed with the DROP-INβ probe (S/B > 3). The rotational freedom of the DROP-IN design and the ability to manipulate the probe with the prograsp tool allowed the surgeon to perform autonomous beta-tracing. CONCLUSIONS: This study demonstrates the feasibility of beta-radioguided surgery in a robotic context by means of a DROP-INβ detector. When translated to an in vivo setting in the future, this technique could provide a valuable tool in detecting tumor remnants on the prostate surface and in confirmation of PSMA-PET positive lymph nodes.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Collamati F, van Oosterom MN, De Simoni M, et al. A DROP-IN beta probe for robot-assisted 68Ga-PSMA radioguided surgery: first ex vivo technology evaluation using prostate cancer specimens. EJNMMI Res. 2020. PMID: 32761408. doi:10.1186/s13550-020-00682-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。